MEI Pharma’s (MEIP) “Hold” Rating Reaffirmed at Stifel Nicolaus

Stifel Nicolaus reaffirmed their hold rating on shares of MEI Pharma (NASDAQ:MEIP) in a research report released on Friday, Benzinga reports. They currently have a $7.00 price target on the stock.

A number of other analysts have also issued reports on the stock. StockNews.com raised shares of MEI Pharma from a hold rating to a buy rating in a research note on Wednesday, February 28th. TheStreet lowered shares of MEI Pharma from a c- rating to a d+ rating in a research note on Thursday, February 1st.

MEI Pharma Stock Down 0.6 %

NASDAQ MEIP opened at $3.25 on Friday. The company has a fifty day moving average of $4.06 and a two-hundred day moving average of $5.46. The firm has a market capitalization of $21.65 million, a price-to-earnings ratio of 1.09 and a beta of 0.77. MEI Pharma has a 52 week low of $3.21 and a 52 week high of $7.97.

MEI Pharma (NASDAQ:MEIP) last posted its quarterly earnings data on Tuesday, February 13th. The company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.20). MEI Pharma had a return on equity of 39.72% and a net margin of 39.06%. Equities research analysts anticipate that MEI Pharma will post 3.24 EPS for the current year.

Institutional Trading of MEI Pharma

Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of MEI Pharma by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 389,807 shares of the company’s stock valued at $2,261,000 after acquiring an additional 6,260 shares in the last quarter. Cable Car Capital LLC bought a new stake in shares of MEI Pharma in the fourth quarter valued at about $3,546,000. Bridgeway Capital Management LLC raised its holdings in shares of MEI Pharma by 46.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 26,869 shares of the company’s stock valued at $156,000 after acquiring an additional 8,500 shares in the last quarter. Northern Trust Corp raised its holdings in shares of MEI Pharma by 134.9% in the fourth quarter. Northern Trust Corp now owns 24,780 shares of the company’s stock valued at $144,000 after acquiring an additional 14,230 shares in the last quarter. Finally, National Bank of Canada FI bought a new stake in shares of MEI Pharma in the fourth quarter valued at about $36,000. 52.38% of the stock is currently owned by institutional investors.

About MEI Pharma

MEI Pharma, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor for the treatment of patients with relapsed/refractory follicular lymphoma; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase I clinical trial for acute myeloid leukemia and B-cell malignancies.